Monjuvi (Tafasitamab-cxix)

  • Brand Name: Monjuvi
  • Innovator Brand Name: Monjuvi
  • API: Tafasitamab-cxix
  • Dosage Form: 1 Vial (Per Box)
  • Strength: 200mg
  • Manufacturer Name: Morphosys US Inc.
Get Price

Description

Monjuvi Uses:

Monjuvi (Tafasitamab) is a CD19-directed cytolytic antibody used along with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for the autologous stem cell transplant (ASCT).

Dosage: The recommended dose of Tafasitamab is 12 mg/kg based on actual body weight administered as an intravenous infusion. Each treatment cycle of Tafasitamab lasts for 28 days. You will receive Tafasitamab on days 1, 4, 8, 15, and 22 during your first cycle. You will receive Tafasitamab on days 1, 8, 15, and 22 during your second and third cycles. After your first 3 cycles, you will receive Tafasitamab once every 2 weeks on days 1 and 15. After 12 cycles, you will receive only Tafasitamab. Administer tafasitamab dosage in combination with lenalidomide 25 mg for a maximum of 12 cycles, then continue it as monotherapy until disease progression or unacceptable toxicity. Tafasitamab should be administered by a healthcare professional with immediate access to emergency equipment and appropriate medical support to manage infusion-related reactions (IRRs).

Side Effects: The most commonly reported monjuvi side effects (incidence ≥20%) include:

  • Neutropenia
  • Fatigue
  • Anemia
  • Diarrhea
  • Thrombocytopenia
  • Cough
  • Pyrexia
  • Peripheral edema
  • Decreased appetite
  • Respiratory tract infection

Warnings and Precautions:

  • Premedicate patients prior to starting monjuvi 200 mg infusion. Monitor patients frequently during infusion.
  • Monitor patients for CBC prior to administration of each treatment cycle and throughout the treatment.
  • Monitor patients with tafasitamab dosing for signs and symptoms of infection and manage infections as appropriate.
  • Monitor patients with neutropenia for the signs and symptoms of infection.
  • The monjuvi drug is initially used along with lenalidomide. This combination is contraindicated in pregnant women, because lenalidomide can cause birth defects and death of the unborn child.
  • Due to the risk for serious adverse reactions in the breastfed child, women should not breastfeed during treatment with tafasitamab-cxix 200 mg and for at least 3 months after the last dose.

Moreinfo

Storage: Store Tafasitamab vial refrigerated at 36°F to 46°F (2°C to 8°C) in the original carton to protect from light. Neither shake nor freeze this medicine.

Availability in India: The Indian Pharma helps connect buyers with suppliers who can ship the MONJUVI at the global level as per the needs of buyer’s. The Indian Pharma provides guarantee of quality as well as delivery for the MONJUVI Injections.

Buying Procedure: In order to buy MONJUVI, you can contact us at our TOLL-FREE Number 1800 889 1064 or on WhatsApp Number +919650877511 or an Email to us at: info@theindianpharma.com along with the legitimate ID Proof, standard Prescription and Medical Reports.

Conclusions: Tafasitamab treatment achieves an impressive clinical benefit for its substantial efficacy improvements over medicine Polivy (polatuzumab vedotin) + bendamustine + rituximab for adult patients with relapsed or refractory diffuse large B-cell lymphoma who have failed single or multiple prior lines of therapy.

FAQ

What is Monjuvi?
Monjuvi is a prescription medicine given with medication lenalidomide to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) that has come back (relapsed) or that did not respond to prior therapy (refractory) and who are not the recipient of stem cell transplant.

What does Monjuvi contain as an active substance?
The medication Monjuvi specifically contains the active substance Tafasitamab-cxix.

How is Tafasitamab-cxix supplied?
Tafasitamab-cxix for injection is a sterile, preservative-free, white to slightly yellowish
lyophilized powder for reconstitution supplied as a 200 mg single-dose vial.

How will I receive my treatment?
Tafasitamab-cxix will be given to you by your health specialist as an intravenous (IV) infusion into one of your veins. You will receive your dose in a clinic or infusion center, so there’s no need to travel to a special cancer center. Your health specialist will also prescribe a 25 mg lenalidomide pill for you to take on days 1’st to 21’st of each treatment cycle, for the first 12 cycles.

How often is Tafasitamab-cxix given?
Each treatment cycle of Tafasitamab-cxix lasts for 28 days.

  • You will receive Tafasitamab-cxix on days 1, 4, 8, 15, and 22 during your first cycle.

  • You will receive Tafasitamab-cxix on days 1, 8, 15, and 22 during your second and third cycles.

  • After your first 3 cycles, you will receive Tafasitamab-cxix once every 2 weeks on days 1 and 15.

  • After 12 cycles, you will receive only Tafasitamab-cxix.
    Your healthcare professional will also prescribe a lenalidomide capsule of 25 mg for you to take on days 1-21 of each treatment cycle, for the first 12 cycles.


How much does monjuvi cost?
The monjuvi price in India usually can vary depending on the wholesaler/pharmacy you visit. Monjuvi is available as a brand name drug only, a generic version is not yet available.

What is the best price for Tafasitamab?
Please contact Toll-free: +91 1800 889 1064|+919650877511 for tafasitamab price in India. We take the guarantee of quality and delivery anywhere in the world as per the buyer’s requirements.

Can I get Monjuvi (Tafasitamab) even if I am not based in India?
The Indian Pharma helps patients in accessing or importing Monjuvi (Tafasitamab), not approved in their home country against the legitimate prescription and in conformity with the all local laws and regulations of their home country.

Reviews

There are no reviews yet.

Be the first to review “Monjuvi (Tafasitamab-cxix)”

Your email address will not be published.

×